A share price of Enanta Pharmaceuticals Inc [ENTA] is currently trading at $8.94, up 11.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The ENTA shares have gain 4.32% over the last week, with a monthly amount drifted -21.23%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enanta Pharmaceuticals Inc [NASDAQ: ENTA] stock has seen the most recent analyst activity on August 09, 2023, when JP Morgan downgraded its rating to a Underweight but kept the price target unchanged to $14 for it. Previously, Jefferies downgraded its rating to Hold on August 08, 2023, and dropped its price target to $18. On December 09, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $56 on the stock. Evercore ISI upgraded its rating to a Outperform but stick to its price target of $62 on July 06, 2022. Evercore ISI upgraded its rating to a In-line but $39 remained the price target by the analyst firm on June 01, 2022. Jefferies started tracking with a Buy rating for this stock on October 07, 2021, and assigned it a price target of $95. In a note dated September 09, 2021, SVB Leerink initiated an Mkt Perform rating and provided a target price of $55 on this stock.
Enanta Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $7.86 and $17.80. Currently, Wall Street analysts expect the stock to reach $65.67 within the next 12 months. Enanta Pharmaceuticals Inc [NASDAQ: ENTA] shares were valued at $8.94 at the most recent close of the market. An investor can expect a potential return of 634.56% based on the average ENTA price forecast.
Analyzing the ENTA fundamentals
Trailing Twelve Months sales for Enanta Pharmaceuticals Inc [NASDAQ:ENTA] were 67.64M which represents -22.84% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -1.8%, Pretax Profit Margin comes in at -1.74%, and Net Profit Margin reading is -1.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.73 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.94 points at the first support level, and at 6.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.57, and for the 2nd resistance point, it is at 10.21.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Enanta Pharmaceuticals Inc [NASDAQ:ENTA] is 5.21. On the other hand, the Quick Ratio is 5.21, and the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 2.80, the price to book ratio is 1.47.
Transactions by insiders
Recent insider trading involved Rottinghaus Scott T., Chief Medical Officer, that happened on Jul 15 ’24 when 5375.0 shares were sold. Chief Medical Officer, Rottinghaus Scott T. completed a deal on Jul 11 ’24 to sell 4299.0 shares. Meanwhile, Chief Medical Officer Rottinghaus Scott T. sold 2271.0 shares on Jul 12 ’24.
